SEC Company Response from Seres Therapeutics, Inc. (MCRB) (CIK 0001609809) (MCRB) — Mar 16, 2020
Seres Therapeutics, Inc. (MCRB) (CIK 0001609809)
Date: March 16, 2020 · CIK: 0001609809 · Accession: 0001193125-20-074860
AI Filing Summary & Sentiment
File numbers found in text: 333-237033
Letter
Via EDGAR Transmission Division of Corporation Finance Securities and Exchange Commission Re: Seres Therapeutics, Inc. Registration Statement on Form S-3 Filed March 9, 2020 Registration No. 333-237033
Dear Mr. Buchmiller:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on March 18, 2020 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Seres Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Peter Handrinos of Latham & Watkins LLP, counsel to the Company, at (617) 948-6060, or in his absence, Wesley C. Holmes at (617) 948-6027, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
200 Sidney Street
Cambridge, MA 02139
Tel: 617-945-9626
www.serestherapeutics.com
Sincerely yours,
Seres Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP 200 Sidney Street Cambridge, MA 02139 Tel: 617-945-9626 www.serestherapeutics.com March 16, 2020 Via EDGAR Transmission Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Seres Therapeutics, Inc. Registration Statement on Form S-3 Filed March 9, 2020 Registration No. 333-237033 Dear Mr. Buchmiller: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on March 18, 2020 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Seres Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Peter Handrinos of Latham & Watkins LLP, counsel to the Company, at (617) 948-6060, or in his absence, Wesley C. Holmes at (617) 948-6027, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. 200 Sidney Street Cambridge, MA 02139 Tel: 617-945-9626 www.serestherapeutics.com Sincerely yours, Seres Therapeutics, Inc. By: /s/ Eric D. Shaff Eric D. Shaff President and Chief Executive Officer cc: Peter N. Handrinos, Esq. Wesley C. Holmes, Esq.